American National Bank & Trust Reduces Stake in AbbVie Inc. $ABBV

American National Bank & Trust lessened its stake in AbbVie Inc. (NYSE:ABBV) by 6.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,406 shares of the company’s stock after selling 4,661 shares during the quarter. AbbVie makes up 1.7% of American National Bank & Trust’s holdings, making the stock its 16th biggest position. American National Bank & Trust’s holdings in AbbVie were worth $18,941,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Worth Asset Management LLC lifted its position in AbbVie by 87.9% during the third quarter. Worth Asset Management LLC now owns 3,501 shares of the company’s stock worth $916,000 after acquiring an additional 1,638 shares during the last quarter. Matrix Trust Co raised its position in shares of AbbVie by 7.1% in the third quarter. Matrix Trust Co now owns 13,447 shares of the company’s stock valued at $3,518,000 after buying an additional 892 shares in the last quarter. Crumly & Associates Inc. raised its holdings in AbbVie by 39.0% in the 3rd quarter. Crumly & Associates Inc. now owns 3,927 shares of the company’s stock valued at $1,027,000 after acquiring an additional 1,102 shares in the last quarter. First Community Trust NA grew its holdings in shares of AbbVie by 9.1% during the 3rd quarter. First Community Trust NA now owns 13,252 shares of the company’s stock worth $3,467,000 after purchasing an additional 1,106 shares in the last quarter. Finally, Weaver Consulting Group raised its stake in AbbVie by 6.8% in the third quarter. Weaver Consulting Group now owns 1,311 shares of the company’s stock valued at $343,000 after purchasing an additional 83 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABBV shares. JPMorgan Chase & Co. raised their target price on AbbVie from $280.00 to $285.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. HSBC increased their price objective on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a report on Thursday, September 10th. BMO Capital Markets upped their price target on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Oppenheimer raised their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Finally, Leerink Partners upped their price objective on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $274.32.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported that Epkinly (epcoritamab) plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL). The Phase 3 trial met its progression-free-survival goal and could support regulatory filings and a larger role for Epkinly in frontline treatment, potentially challenging Roche’s Polivy. AbbVie and Genmab Epkinly DLBCL results
• Positive Sentiment: The FDA granted two Breakthrough Therapy Designations to AbbVie’s investigational antibody-drug conjugate telisotuzumab adizutecan (Temab-A or ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations strengthen AbbVie’s oncology pipeline, although the drug remains investigational and commercial success is not assured. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: Scotiabank raised its AbbVie price target from $280 to $320 and maintained a “sector outperform” rating, adding to bullish Wall Street sentiment. Analysts cited AbbVie’s pipeline and growth prospects as reasons for further upside. Scotiabank raises AbbVie price target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later in October, making upcoming earnings, guidance and pipeline commentary potential near-term catalysts. AbbVie upcoming third-quarter earnings
• Negative Sentiment: AbbVie updated third-quarter adjusted EPS guidance to $3.73-$3.77 after recording $216 million in acquired in-process research and development and milestone expenses. The expense reduced full-year adjusted EPS guidance by $0.11 and places the quarterly range below the cited consensus estimate of $3.85. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Some coverage highlights AbbVie’s elevated reported payout ratio, estimated at roughly 190%, raising questions about dividend coverage. However, this measure can be distorted by accounting items and should be assessed alongside cash flow, adjusted earnings and the company’s strong recent revenue growth. AbbVie dividend payout analysis

AbbVie Price Performance

Shares of ABBV stock traded up $7.09 during trading hours on Wednesday, reaching $273.78. The company had a trading volume of 1,927,853 shares, compared to its average volume of 6,412,232. The business has a fifty day simple moving average of $258.12 and a 200-day simple moving average of $235.42. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $274.94. The company has a market cap of $483.72 billion, a price-to-earnings ratio of 77.34, a price-to-earnings-growth ratio of 1.20 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the firm earned $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts expect that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is currently 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.